Bioanalytical interferences in immunoassays for antibody biotherapeutics

Bioanalysis

Volumn 3, Issue 7, 2011, Pages 703-706

  Pendley, Charles ^a   Shankar, Gopi ^a  

^a CENTOCOR INC   (United States)

Author keywords

ADA; antidrug antibody; bioanalysis; immunoassays; interferent; ligand binding assays; monoclonal antibody; PK; serum concentration

Indexed keywords

MONOCLONAL ANTIBODY;

ANTIGEN BINDING; BIOTECHNOLOGY; CONCENTRATION RESPONSE; CROSS REACTION; DRUG DEVELOPMENT; DRUG HALF LIFE; IMMUNOASSAY; PERFORMANCE; QUANTITATIVE ANALYSIS; REVIEW; VALIDATION STUDY;

ANTIBODIES; BIOLOGICAL MARKERS; CHEMISTRY TECHNIQUES, ANALYTICAL; HUMANS; IMMUNOASSAY;

EID: 79953658382     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.53     Document Type: Review

References (8)

1. Wu JT. Quantitative Immunoassay: A Practical Guide for Assay Establishment, Troubleshooting, and Clinical Application. AACC Press, Washington, DC, USA 255 (2000).
2. Wadhwa M, Bird C, Dilger P, Gaines-Das R, Thorpe R. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biological. J. Immunol. Meth. 278, 1-17 (2003). (Pubitemid 37281188)
3. Lee J, Kelley M, King L et al. Bioanalytical approaches to quantify 'total ' and 'free' therapeutic antibodies and their targets: technical challenges and PK/PD application over the course of drug development. AAPS J. 13, 99-110 (2011).
4. DeSilva B, Smith W, Weiner R et al. Recommendation for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20, 1885-1900 (2003). (Pubitemid 37449466)
5. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48, 1267-1281 (2008).
6. US FDA, Center For Drug Evaluation and Research (CDER), Center For Biologics Evaluation and Research (CBER). Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins (2009).
7. Boscato L, Stuart M. Heterophilic antibodies: a problem for all immunoassays. Clin. Chem. 34, 27-343 (1988).
8. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8, 226-234 (2009).